...
首页> 外文期刊>Biological trace element research >Whether Metal Element-Containing Herbal Formula Angong Niuhuang Pill Is Safe for Acute Brain Disorders?
【24h】

Whether Metal Element-Containing Herbal Formula Angong Niuhuang Pill Is Safe for Acute Brain Disorders?

机译:含金属元素的草药配方安宫牛黄丸对急性脑疾病是否安全?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

"Angong Niuhuang Pill" (AGNH Pill) has been used as patented herbal formula for treatment of acute brain disorders including ischemic stroke, hemorrhage stroke, and trauma brain injury in traditional Chinese medicine for a thousand years. It is widely used in treatment of many diseases. As AGNH Pill contains metal elements named realgar and cinnabar, whether AGNH Pill is safe attracts great concerns. To address this question, we reviewed adverse drug reactions (ADR) and adverse events (AE) to assess the safety of AGNH Pill clinically. We searched PubMed, Embase, Cochrane library, TOXNET, and Chinese databases CNKI and Wanfang for articles published between January 1974 and January 2015. A total of 49 cases contained in 10 articles were included in this study. We were unable to determine the frequency of ADR/AE induced by AGNH Pill due to the lack of complete production and market information provided by pharmaceutical manufacturers and hospitals. Based on current literature data, we estimated that the risk of ADR/AE from AGNH Pill administration was low. The majority of ADR/AE was attributed to the improper use of AGNH Pill, such as use in children with overdosage or use with incompatible drugs. We were unable to distinguish whether incidents were ADR or AE because of the poor reports. To date, published evidence indicates that AGNH Pill appears to carry a relatively low risk of ADR/AE. As the quality of clinical assessment for the safety of AGNH Pill is poor, it is desirable to conduct well-designed randomized clinical trials to assess its safety for the treatment of acute brain disorders.
机译:“安宫牛黄丸”(AGNH丸)作为具有专利权的草药配方,已用于治疗中药等急性脑部疾病,包括缺血性中风,出血性中风和脑外伤。它被广泛用于治疗许多疾病。由于AGNH药丸含有称为雄黄和朱砂的金属元素,因此AGNH药丸是否安全引起极大关注。为了解决这个问题,我们审查了药物不良反应(ADR)和不良事件(AE),以评估AGNH Pill在临床上的安全性。我们在PubMed,Embase,Cochrane图书馆,TOXNET以及中国数据库CNKI和Wanfang中搜索了1974年1月至2015年1月之间发表的文章。该研究共纳入10篇文章中的49例。由于缺乏药品制造商和医院提供的完整生产和市场信息,我们无法确定AGNH Pill引起的ADR / AE发生频率。根据目前的文献数据,我们估计AGNH丸给药引起ADR / AE的风险较低。 ADR / AE的大部分归因于AGNH药丸的不当使用,例如用于剂量过量的儿童或与不相容的药物一起使用。由于报道不力,我们无法区分事件是ADR还是AE。迄今为止,已公开的证据表明,AGNH丸似乎具有相对较低的ADR / AE风险。由于AGNH丸安全性的临床评估质量较差,因此需要进行精心设计的随机临床试验来评估其对急性脑部疾病的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号